Di Wang
Senior Biostatistician
Expertise:
Di is a senior biostatistician on Value & Evidence team at EVERSANA, with extensive experience in conducting indirect treatment comparisons.
Since joining EVRSANA in 2022, Di has been involved in the implementation of various indirect comparisons, including inverse probability of treatment weighting, propensity score matching, matching-adjusted indirect comparison, meta-analysis and network meta-analysis. Di is skilled and detail-oriented. Prior joining EVERSANA, she worked for Praxis Spinal Cord Institute as a biostatistician, responsible for conducting statistical analysis on administration data. Di holds an MSc in Statistics from Acadia University
Articles by Di Wang
Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate for metastatic prostate cancer remains low (~34%). Encouragingly, multiple randomized clinical trials have recently demonstrated promising responses to novel poly (ADP-ribose) polymerase (PARP) inhibitors – such as talazoparib, niraparib and olaparib, in combination with androgen receptor pathway inhibitors – and represent a new class of therapies for first-line treatment of mCRPC. However, there has been no direct comparative trial conducted between these combinations of PARP and androgen receptor pathway inhibitors. When such trial data […]